Dementia Associated with Alzheimer's Disease Pipeline Insight 2025

Strategic Insights -

Dementia associated with Alzheimer's disease is a general term that refers to a serious decline in cognitive function severe enough to interfere with daily life. The most common cause of dementia is Alzheimer's disease (AD), which accounts for about two-thirds of cases in individuals aged 65 and older. Alzheimer's is a progressive neurodegenerative disorder marked by the gradual deterioration of memory, thinking, language, and behavioral abilities. With currently no cure available, treatments aim to manage symptoms and improve the quality of life for patients and caregivers.

Key Takeaways:

  • DelveInsight's Dementia associated with Alzheimer's Disease pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Dementia associated with Alzheimer's Disease treatment.
  • In September 2025, Japan's Ministry of Health, Labour, and Welfare approved KISUNLA (donanemab-azbt, 350 mg/20 mL) for intravenous infusion every four weeks, developed by Eli Lilly, for adults with early symptomatic Alzheimer's disease, including mild dementia, who have confirmed amyloid pathology.
  • In July 2025, the FDA approved Eli Lilly's donanemab, an anti-amyloid antibody, making it the third drug intended to modify the progression of Alzheimer's disease.
  • Key Dementia associated with Alzheimer's Disease companies such as BioVie, Karuna Therapeutics, Cassava Sciences, Inc., Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., and others are evaluating new drugs for Dementia associated with Alzheimer's Disease to improve the treatment landscape.
  • Promising Dementia associated with Alzheimer's Disease pipeline therapies in various stages of development include NE3107, KarXT, Simufilam, CT-1812, CM383, and others.
  • BioVie, Karuna Therapeutics, and Cassava Sciences have advanced their drug candidates to the most progressed stage of development-Phase III clinical trials.

Statistics:

  • 80+ active companies are working to develop 100+ pipeline therapies for Dementia associated with Alzheimer's Disease treatment.
  • Among the key companies, BioVie, Karuna Therapeutics, and Cassava Sciences have advanced their drug candidates to the most progressed stage of development-Phase III clinical trials.
  • In September 2025, KISUNLA (donanemab-azbt, 350 mg/20 mL) was approved for intravenous infusion every four weeks.
  • In July 2025, the FDA approved Eli Lilly's donanemab, an anti-amyloid antibody.

Sources:

  • DelveInsight's "Dementia Associated with Alzheimer's Disease Pipeline Insight, 2025" report
  • M2 PressWIRE-July 9, 2025-: Dementia associated with Alzheimer's Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | BioVie, Karuna Therapeutics, Cassava Sciences (C)1994-2025 M2 COMMUNICATIONS RDATE:08072025
  • www.abnewswire.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.m2.co.uk on the world wide web. Inquiries to info@m2.co.uk)).